Forecast for Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
NIH Blueprint MedTech program will offer funding and support to develop innovative medical devices for nervous system disorders, aiming to accelerate their translation to clinical use.
Funder: National Institutes of Health (NIH)
Due Dates: September 29, 2025 | January 28, 2026 | May 28, 2026 | September 28, 2026 | January 28, 2027 | May 28, 2027 | September 28, 2027 | January 28, 2028
Funding Amounts: No budget cap; project periods: UG3 up to 4 years, UH3 up to 4 years, total max 5 years; budgets must be justified by project needs.
Summary: Supports translational activities and clinical studies for medical devices to prevent, monitor, diagnose, or treat nervous system disorders, accelerating device development toward first-in-human studies.
Key Information: Milestone-driven UG3/UH3 cooperative agreement; strict application requirements and required pre-application consultation with NIH recommended.
Description
This NIH opportunity funds translational and clinical research to advance the development of medical devices for disorders within the missions of participating NIH institutes and centers, especially those affecting the nervous or neuromuscular systems. The program aims to accelerate the translation of novel medical device technologies from early-stage development toward first-in-human clinical studies, providing both funding and access to specialized NIH-supported translational resources, regulatory guidance, and commercialization support.
Projects must address a clear unmet clinical need and demonstrate significant innovation or improvement over existing technologies. The program is structured as a two-phase, milestone-driven cooperative agreement (UG3/UH3), with NIH staff actively participating in project planning, milestone negotiation, and progress monitoring.
